ABVC BioPharma (NASDAQ:ABVC) Trading Down 2.7% – Time to Sell?

ABVC BioPharma, Inc. (NASDAQ:ABVC)’s share price dropped 2.7% during mid-day trading on Wednesday . The company traded as low as $1.3750 and last traded at $1.42. Approximately 50,293 shares traded hands during trading, a decline of 4% from the average daily volume of 52,436 shares. The stock had previously closed at $1.46.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of ABVC BioPharma in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has a consensus rating of “Sell”.

ABVC BioPharma Stock Down 7.3%

The firm has a 50 day moving average price of $1.77 and a 200-day moving average price of $2.39.

ABVC BioPharma (NASDAQ:ABVC) last released its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.11) earnings per share for the quarter.

Institutional Investors Weigh In On ABVC BioPharma

Institutional investors have recently made changes to their positions in the company. Citadel Advisors LLC purchased a new position in shares of ABVC BioPharma during the 3rd quarter worth about $48,000. Millennium Management LLC purchased a new stake in ABVC BioPharma in the 3rd quarter worth about $60,000. Finally, Geode Capital Management LLC raised its position in ABVC BioPharma by 5.8% in the 2nd quarter. Geode Capital Management LLC now owns 110,499 shares of the company’s stock worth $246,000 after purchasing an additional 6,017 shares during the period. Institutional investors own 11.38% of the company’s stock.

ABVC BioPharma Company Profile

ABVC BioPharma is a clinical-stage biotechnology company focused on the discovery and development of novel vaccine and immunotherapy candidates for oncology and infectious diseases. The company leverages a proprietary peptide-based platform to identify and synthesize immunogenic epitopes, aiming to stimulate targeted immune responses against tumor-associated and pathogen-derived antigens.

The company’s pipeline includes active immunotherapy programs designed to address a range of cancer indications, along with vaccine candidates targeting bacterial pathogens.